US Food and Drug Administration (USFDA) has red flagged Lupin for significant violations of the current good manufacturing practice regulations at its Mandideep facility in Madhya Pradesh. The violations pointed out in a warning letter by the USFDA include inadequacy of the cleaning process for manufacturing equipment.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.